MARTA
GÓMEZ ALMERÍA
Predoctoral FPI
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (6)
2022
-
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy
Journal of Medicinal Chemistry, Vol. 65, Núm. 2, pp. 1585-1607
2021
-
Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 22
-
Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Brain Pathology, Vol. 31, Núm. 6
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387
-
Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 16